Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bellavie Immuno
- Development stage
- Unknown
- Lead developer
- BellaVie
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bellavie Immuno is a synbiotic dietary supplement developed by the Belgian laboratory BellaVie and marketed in Egypt by Rameda. It is formulated to support and strengthen the immune system and maintain a healthy gut microbiota balance. The product is delivered in gastro-resistant capsules and contains a blend of eight probiotic strains (*Bacillus coagulans*, *Bifidobacterium breve*, *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, and *Saccharomyces boulardii*), prebiotic inulin fiber, and nutraceuticals including Vitamin C (derived from Camu-Camu extract) and Vitamin D3.
- Brand names
- BellaVie Immuno
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Bellavie Immuno.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bellavie Immuno.